Skip to main content
Clinical Trials/DRKS00031143
DRKS00031143
Completed
Not Applicable

Sample collection for an assay development to determine HSV-specific T-cell responses in blood samples from HSV-2 infected individuals and HSV-1 + HSV-2 infected individuals - HTXTCELL-01

Heidelberg ImmunoTherapeutics GmbH0 sites29 target enrollmentJuly 21, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
genital herpesoral herpes
Sponsor
Heidelberg ImmunoTherapeutics GmbH
Enrollment
29
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 21, 2023
End Date
June 28, 2023
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • The subject is at least 18 years old and capable of giving consent.
  • Present consent to participate in the study.
  • Proven seropositivity for HSV\-2 or HSV\-2 and HSV\-1 combined.

Exclusion Criteria

  • Any disease or condition that does not medically permit blood sampling in the opinion of the physician providing information.
  • Positive serostatus for HIV, hepatitis B or hepatitis C.
  • Previous treatment with the antibody HDIT 101 (former MATCH\-2 study patients who received placebo may be included).
  • Vaccination with an HSV 1/2 vaccine (e.g. experimental)

Outcomes

Primary Outcomes

Not specified

Similar Trials